

Gonzalo Blanco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745089/publications.pdf>

Version: 2024-02-01

14
papers

186
citations

1684188

5
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

510
citing authors

#	ARTICLE	IF	CITATIONS
1	SÃ©zary syndrome patient-derived models allow drug selection for personalized therapy. <i>Blood Advances</i> , 2022, , .	5.2	0
2	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	6.2	1
3	Reduced expansion of CD94/NKG2C ⁺ NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or <i>NKG2C</i> deletions. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1032-1040.	1.3	6
4	Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2021, 95, 68-80.	0.4	6
5	Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. <i>Blood</i> , 2019, 134, 4287-4287.	1.4	1
6	Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3027-3027.	1.4	0
7	Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 5457-5457.	1.4	1
8	Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?. <i>Blood</i> , 2019, 134, 3029-3029.	1.4	0
9	Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. <i>Oncotarget</i> , 2018, 7, e1432328.	4.6	20
10	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i> aberrations. <i>Oncotarget</i> , 2016, 7, 80916-80924.	1.8	29
11	Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. <i>BioMed Research International</i> , 2014, 2014, 1-13.	1.9	106
12	Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 788-797.	2.8	15
13	Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study. <i>Blood</i> , 2014, 124, 4675-4675.	1.4	1
14	Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p). <i>Blood</i> , 2014, 124, 5638-5638.	1.4	0